Population pharmacokinetics of blonanserin in Chinese healthy volunteers and the effect of the food intake

Human Psychopharmacology

Volumn 28, Issue 2, 2013, Pages 134-141

  Wen, Yu Guan ^a   Shang, De Wei ^a   Xie, He Zhi ^b   Wang, Xi Pei ^c   Ni, Xiao Jia ^a   Zhang, Ming ^a   Lu, Wei ^d   Qiu, Chang ^a   Liu, Xia ^a   Li, Fang Fang ^e   Li, Xuan ^a   Luo, Fu Tian ^f  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b Livzon Pharmaceutical Institute   (China)

^c GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^d PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^e GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

^f SUN YAT SEN UNIVERSITY   (China)

Author keywords

blonanserin; clinical trial; food effect; NONMEM; population pharmacokinetics

Indexed keywords

BLONANSERIN;

ADULT; AKATHISIA; ARTICLE; ASTHENIA; CHINESE; COMPARTMENT MODEL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FIRST PASS EFFECT; FOOD DRUG INTERACTION; FOOD INTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MORNING DOSAGE; NORMAL HUMAN; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; POPULATION PHARMACOKINETICS; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SIMULATION; SINGLE DRUG DOSE; SOMNOLENCE; TANDEM MASS SPECTROMETRY;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; EATING; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; MALE; PIPERAZINES; PIPERIDINES; YOUNG ADULT;

EID: 84875685915     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2290     Document Type: Article

References (16)

1. Chang M, Li L,. 2010. A new antipsychotic agent: blonanserin. Chin J New Drugs Clin Rem 29: 571-575.
2. Comets E, Brendel K, Mentre F,. 2008. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed 90: 154-166.
3. Deeks ED, Keating GM,. 2010. Blonanserin: a review of its use in the management of schizophrenia. CNS Drugs 24: 65-84.
4. Fleisher D, Li C, Zhou Y, et al,. 1999. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Clin Pharmacokinet 36: 233-254.
5. Garcia E, Robert M, Peris F, et al,. 2009. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study. CNS Drugs 23: 615-625.
6. Jonsson EN, Karlsson MO,. 1999. Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58: 51-364.
7. Lindbom L, Ribbing J, Jonsson EN,. 2004. Perl-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming. Comput Methods Programs Biomed 75: 85-94.
8. Lonasen, (blonanserin) [product information]. 2009. Dainippon Sumitomo Pharma Corp, Japan. (in Japanese).
9. Ogawa T, Hattori H, Kaneko R, et al,. 2010. Sensitive analysis of blonanserin, a novel antipsychotic agent, in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry. Anal Sci 26: 1099-1102.
10. Ohno Y, Okano M, Imaki J, et al,. 2010. Atypical antipsychotic properties of blonanserin, a novel dopamine D2 and 5-HT2A antagonist. Pharmacol Biochem Behav 96: 175-180.
11. Saruwatari J, Yasui-Furukori N, Inoue Y, et al,. 2010. Effect of dose timing in relation to food intake on systemic exposure to blonanserin. Eur J Clin Pharmacol 66: 899-902.
12. Singh BN,. Effects of food on clinical pharmacokinetics. 1999. Clin Pharmacokinet 37: 213-255.
13. Suzuki H, Gen K,. 2012. The relationship between the plasma concentration of blonanserin, and its plasma anti-serotonin 5-HT(2A) activity/anti-dopamine D(2) activity ratio and drug-induced extrapyramidal symptoms. Psychiatry Clin Neurosci 66: 146-152.
14. Team R,. 2010. A Language and Environment for Statistical Computing. R Foundation for Statistical Computing Vienna Austria. http://www.R-project.org.
15. Wen YG, Ni XJ, Zhang M, et al,. 2012. Simultaneous determination of blonanserin and its metabolite in human plasma and urine by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 903: 46-52.
16. Yang J, Bahk WM, Cho HS, et al,. 2010. Efficacy and tolerability of blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial. Clin Neuropharmacol 33: 169-175.